Frontiers in pharmacology2026ReviewNon-viral Gene DeliveryDrug Delivery
Rachamala Hk, Atla S, Angom Rs
Cancer immunotherapy is a transformative technology allowing for the elimination of malignant cells through immune system stimulation; however, the large-scale clinical application of adoptive cellular therapy technologies is limited due to difficulties in ex vivo immune cell engineering, high costs, and complicated manufacturing process. Recently, in vivo immune cell engineering was discovered as an emerging approach that allows for the genetic reprogramming of immune cells in patients, thus circumventing many problems inherent to traditional cellular therapy technologies.
Read the article →Journal of controlled release : official journal of the Controlled Release Society2026ResearchNon-viral Gene DeliveryDrug Delivery
Jacobs W, De Zwaan K, Rutten L, Van Wessel T, Boltje Tj, Cano Lq, Et Al.
Non-viral nanocarriers for oligonucleotide delivery have enormous therapeutic potential, but the factors determining cell type-specific uptake remain incompletely understood. One major cell surface component that delivery vectors encounter is the glycocalyx. While membrane glycans are established interactors for many viruses, their impact on non-viral particles has remained underexplored. Here, we show that the role of membrane glycosaminoglycans (GAGs) in mRNA delivery differs across nanocarrier categories and cell types.
Read the article →Angewandte Chemie (International ed. in English)2026ResearchNon-viral Gene DeliveryDrug Delivery
Gan J, Wang Y, Li M, Cui S, Zhu L, Yu X, Et Al.
Lipid nanoparticles (LNPs) have emerged as a promising platform for gene/drug delivery in cancer therapy, however their nonspecific biodistribution and extensive hepatosplenic sequestration result in insufficient intratumoral accumulation, thereby undermining the therapeutic efficacy. Here, we establish a sequential pretargeting strategy exploiting the high-affinity host-guest recognition between adamantane (ADA) and cucurbit[7]uril (CB[7]) to enhance tumor enrichment.
Read the article →Journal of controlled release : official journal of the Controlled Release Society2026ResearchNon-viral Gene DeliveryDrug Delivery
Nasr Ss, Tabah Oe, Kumar S, Poore S, Duncan Ga
Pulmonary delivery of lipid nanoparticles (LNPs) remains an area of significant interest, given the broad range of genetic disorders that could be addressed through localized administration of therapeutic nucleic acids to the lung. In this study, we investigated how incorporation of the clinically used lung surfactant cocktail Poractant alfa affects the in vitro and in vivo transfection performance of mRNA-loaded LNPs.
Read the article →ACS applied bio materials2026ResearchDrug Delivery
Kumar A, Patri Sv, Chilumula S, Arjunan P, Ayyanar V, Hanchate P, Et Al.
The clinical effectiveness of doxorubicin (DOX) in hepatocellular carcinoma (HCC) remains constrained by poor tumor selectivity and the emergence of multidrug resistance. In this work, we examine how the electronic nature of the C-5 substituent on uracil-based nucleoside lipids shapes the physicochemical and biological behavior of DOX-loaded lipid nanoparticles (LNPs).
Read the article →Advances in Colloid and Interface Science2026ReviewNon-viral Gene DeliveryDrug Delivery
D Zhi, A Halemaimaiti, B Dai, H Li, H Wang, Z Zhang, J Yu, S Zhang
This review examines how lipid structure and formulation affect the delivery of DNA, mRNA and siRNA by lipid nanoparticles, while assessing tissue targeting, safety and clinical translation challenges.
Read the article →BioDrugs2026ReviewNon-viral Gene DeliveryDrug Delivery
U Iqbal, Rw Hwang, Wj Costain
A review of blood–brain barrier transport mechanisms and emerging lipid nanoparticle strategies for carrying nucleic acid and other complex therapies into the central nervous system.
Read the article →Small2025ReviewNon-viral Gene DeliveryDrug Delivery
S Sarmah, S Baidya, M De
This review surveys lipid nanoparticle composition, ionisable lipid synthesis and strategies to target delivery of fragile RNA therapeutics while addressing tissue selectivity and immune activation.
Read the article →Molecular Therapy Methods & Clinical Development2025ReviewNon-viral Gene Delivery
Ca Brimacombe, Ja Kulkarni, Mhy Cheng, K An, D Witzigmann, Pr Cullis
A review of the physical principles and development history behind siRNA lipid nanoparticles for liver gene silencing and mRNA lipid nanoparticles for protein expression.
Read the article →Nature Reviews Drug Discovery2024ReviewNon-viral Gene DeliveryDrug Delivery
Pr Cullis, Pl Felgner
This historical review traces lipid-based gene delivery from cationic lipoplexes to ionisable lipid nanoparticles, connecting foundational research with approved mRNA vaccines and siRNA therapy.
Read the article →